Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rafael Holdings, Inc. Class B Common Stock (NY:RFL)

1.050 +0.050 (+5.00%)
Delayed Quote Updated: 1:06 PM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Rafael Holdings, Inc. Class B Common Stock

< Previous 1 2 Next >
News headline image
Rafael Holdings to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Corporate Update
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
Rafael Holdings Announces Submission of New Drug Application to FDA for Trappsol® Cyclo™ (remibetadex) for the Treatment of Niemann-Pick Disease Type C
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Rafael Holdings, Inc. - RFL
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL
From Pomerantz LLP
Via GlobeNewswire
News headline image
Rafael Holdings Announces Topline Results from the Pivotal Phase 3 TransportNPC™ Study of Trappsol® Cyclo™ in Niemann-Pick Disease Type C (NPC)
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer’s Disease”
License of the MIT patent strengthens Rafael’s intellectual property around cyclodextrins as an Active Pharmaceutical Ingredient (API) in the treatment of ApoE4-positive Alzheimer’s Disease 
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
Rafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM)
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
Rafael Holdings Announces Continuation of its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Following Independent Data Monitoring Committee (DMC) Review of Prespecified 48-Week Interim Data
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results
Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the... 
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
Rafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals
Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the... 
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results
Upon completion of our proposed merger with Cyclo Therapeutics the Company intends to focus its efforts on Cyclo’s lead clinical program Trappsol® Cyclo™ 
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
Our proposed merger with Cyclo Therapeutics advances our strategy to invest in, develop and commercialize clinical stage assets which address areas of high unmet medical need 
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CDE, SMC, COFS, RFL on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BTTR, RVNC, ARC, RFL on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.